摘要
目的探讨生长抑素治疗Ⅰ型肝肾综合征的临床效果。方法选择2010年6月～2012年8月本院收治的56例确诊为Ⅰ型肝肾综合征患者,将患者随机分为对照组和治疗组,每组各28例。对照组给予肝病基础、白蛋白及呋塞米治疗,治疗组在对照组的基础上给予生长抑素持续静脉泵入(250μg/h)。分别观察两组患者的血肌酐(SCr)、尿素氮(BUN)及尿量变化。结果治疗前两组患者各项指标差异无统计学意义,治疗结束后,治疗组患者的肾功能SCr、BUN及尿量等指标均显著优于对照组(P<0.01)。治疗组有效率为46.4%,显著高于对照组的21.4%(P<0.05)。结论生长抑素对于Ⅰ型肝肾综合征疗效良好,患者病情明显好转,临床应用前景广阔。
Objective To investigate clinical effect of somatostatin treatment for type I hepatorenal syndrome. Meth- ods 56 patients with type I hepatorenal syndrome in our hospital from June 2010 to August 2012 were divided into the control group and treatment group,each group of 28 cases,the control group treated by basic,serum albumin and furosemide treated,and the treatment group treated by somatostatin（250 ~g/h） on the basis of control group.The serum ereatinine （SCr）,blood urea nitrogen （BUN）,and urine output change of two groups were analyzed. Results Before treat- ment,the two groups showed no significant differences.After treatment,the renal SCR,BUN and urine output and other indicators were significantly better than that of the control group （P〈0.01）.The total effective rate of the treatment group （46.4%） was significantly higher than that of the control group （21.4%） （P〈0.05）. Conclusion Somatostatin in the treatment of type I hepatorenal syndrome have excellent outcomes and the patient＇s condition is improved markedly.
出处
《中国当代医药》
2013年第25期57-58,共2页
China Modern Medicine
关键词
生长抑素
Ⅰ型肝肾综合征
肝功能衰竭
严重并发症
Somatostatin
Type I hepatorenal syndrome
Liver failure
Serious complications
